Barry Manilow reveals he has lung cancer and will reschedule shows to undergo surgery
“Barry Manilow announced Monday that he has lung cancer and will reschedule his January shows to undergo surgery. The 82-year-old singer-songwriter revealed the diagnosis in a statement shared via Instagram on Monday. He said that he recently had bronchitis for two periods of multiple weeks, so his doctor ordered an MRI out of precaution.”
Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer
“The LATIFY Phase III trial of ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) versus standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The trial evaluated patients without actionable genomic alterations (AGAs) whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.”
Brain metastasis from non-small cell lung cancer: crosstalk between cancer cells and tumor microenvironment components
“The majority of patients with lung cancer are diagnosed at an advanced stage, with a substantial proportion exhibiting signs of brain metastases (BMs). BM is associated with debilitating symptoms, including headaches, seizures and neurological or cognitive impairments, which severely impact the quality of life of patients.”
Lung cancer disparities in rural, persistent poverty counties: a secondary data analysis
“In the US, lung cancer burden is greater in counties that are either rural or in persistent poverty. This study examined lung cancer risk (e.g., smoking), incidence, and mortality across four county types defined by cross-classification of rurality and persistent poverty.”
Patient deaths put Merck, Daiichi’s ADC trial on partial hold
“The Food and Drug Administration has put a partial clinical hold on one of Merck & Co. and Daiichi Sankyo’s antibody-drug conjugates following an unexpected number of deaths in a late-stage clinical trial. Daiichi initiated a voluntary pause recruiting and enrolling the trial, called IDeate-Lung02, after “higher than anticipated incidence of grade 5 interstitial lung disease events,” a spokesperson for Merck and Daiichi said in a statement to BioPharma Dive. Following the pause, the FDA verbally placed the trial on a partial clinical hold in October. The spokesperson did not say the number of deaths recorded.”
US FDA grants priority vouchers to Merck’s cholesterol pill, cancer therapy
“Merck’s cancer therapy, sac-TMT, like other antibody-drug conjugates, is designed to deliver an anti-cancer drug more precisely to malignant cells, causing less damage to healthy tissues than chemotherapy.”
New Blood Test Detects Single Lung Cancer Cell
“FT-IR microspectroscopy blood test detected a single circulating tumor cell (CTC) in one patient with lung cancer, cytospun raw blood sample.”
Expanding the immunotherapy universe in extensive-stage small cell lung cancer: from chemoimmunotherapy backbone to next-wave combinations
“This Review provides a comprehensive, evidence-based map of the evolving ES-SCLC immunotherapy combination landscape. We critically dissect competing therapeutic paradigms, juxtapose corroborative and contradictory data, and distill actionable insights for future trial design, biomarker development, and regulatory strategy.”
30-year smoking duration-based criteria could increase lung cancer screening
“Thirty-year smoking duration-based criteria could reduce eligibility gaps for all races relative to whites, while improving six-year lung cancer detection sensitivity, according to a study published online Dec. 16 in the Annals of Internal Medicine.”
Multidisciplinary Screening Program Dramatically Improves Lung Cancer Detection
“Lung cancer screening rates more than doubled to reach 71.6% after the launch of a coordinated lung cancer screening program in the UR Medicine primary care network in Rochester, New York. Researchers reported on the program in NEJM Catalyst. “My hope is that by sharing our success, others will be able to adopt and build upon what we’re doing to screen more patients and save more lives nationwide,” said corresponding author Robert Fortuna, MD, MPH, a professor at the University of Rochester Medical Center (URMC), Rochester, New York, in a news release.”
Study finds a new protein target against KRAS-driven non-small cell lung cancer
“In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target and developed a drug to treat non-small cell lung cancers that have KRAS mutations.”
OncoPrism-NSCLC Test Predicts Key Clinical Outcomes in Lung Cancer
“Results from the observational PREDAPT trial (NCT04510129) supported the utility of the OncoPrism-non–small cell lung cancer (NSCLC) test, a clinical tool to identify which patients with late-stage NSCLC are most likely to benefit from immune checkpoint inhibitor (ICI) therapy, according to a press release from the developer, Cofactor Genomics.”
Enlighten Me: ChristianaCare Gene Editing Institute delivers lung cancer treatment breakthrough
“The breakthrough reverses chemotherapy resistance, and the hope is this research will help develop the same results for other cancers in the future.”
